Showing: 1 - 3 of 3 RESULTS

England and Tottenham on collision course over Harry Kane’s fitness

José Mourinho is strongly against Gareth Southgate’s plan to start Harry Kane for England in the Nations League tie with Denmark on Wednesday night and has communicated his concerns to the national setup.

The Tottenham manager had urged his England counterpart to handle Kane with care during the international window, given his high workload in the season so far, and the situation became more delicate when the striker felt an issue with his thigh last week.

Related: England’s class of 2018 return favour as Southgate looks back to go forward | David Hytner

Southgate has said Kane is not injured, rather he began to suffer from “muscle fatigue” last Wednesday when he started to train with England, having been given the Monday and Tuesday off. The Football Association sent him for a scan and there has been regular dialogue between their medics and those at Spurs.

Kane was never going to feature last Thursday in the against Wales, which England won 3-0 and, because he was unable to train fully, he was used only as a 66th-minute substitute in the 2-1 Nations League victory against Belgium on Sunday.

But now club and country are on a collision course, with Southgate wanting to start Kane against Denmark. Spurs argue that the fact Kane was sent for a scan shows the FA is worried that the player is carrying something, and they also know he will always turn out when asked to do so. The club blame the FA in part for the number of games Kane has already played this season. Before Belgium he had played 10 in 29 days – eight of them as a starter.

“Medically, there’s been conversations [with Spurs],” Southgate said. “He started to train on the Wednesday, was a little unhappy with how he felt, so then worked with our medical team the next couple of days. We scanned just to be certain but it’s a muscular fatigue issue rather than an injury so it just needed a bit more confidence.

“He knew by then he could push on a little bit but he just needed a bit more confidence in it and so his training week really wasn’t suitable to start [against Belgium]. I think he’ll have gained more confidence from the spell he had [as a substitute] and so, all being well, we hope he’ll be good to start on Wednesday.”

Source Article

England and Tottenham on collision course over Harry Kane’s fitness | Football

José Mourinho is strongly against Gareth Southgate’s plan to start Harry Kane for England in the Nations League tie with Denmark on Wednesday night and has communicated his concerns to the national setup.

The Tottenham manager had urged his England counterpart to handle Kane with care during the international window, given his high workload in the season so far, and the situation became more delicate when the striker felt an issue with his thigh last week.

Southgate has said Kane is not injured, rather he began to suffer from “muscle fatigue” last Wednesday when he started to train with England, having been given the Monday and Tuesday off. The Football Association sent him for a scan and there has been regular dialogue between their medics and those at Spurs.

Kane was never going to feature last Thursday in the against Wales, which England won 3-0 and, because he was unable to train fully, he was used only as a 66th-minute substitute in the 2-1 Nations League victory against Belgium on Sunday.

But now club and country are on a collision course, with Southgate wanting to start Kane against Denmark. Spurs argue that the fact Kane was sent for a scan shows the FA is worried that the player is carrying something, and they also know he will always turn out when asked to do so. The club blame the FA in part for the number of games Kane has already played this season. Before Belgium he had played 10 in 29 days – eight of them as a starter.

“Medically, there’s been conversations [with Spurs],” Southgate said. “He started to train on the Wednesday, was a little unhappy with how he felt, so then worked with our medical team the next couple of days. We scanned just to be certain but it’s a muscular fatigue issue rather than an injury so it just needed a bit more confidence.

“He knew by then he could push on a little bit but he just needed a bit more confidence in it and so his training week really wasn’t suitable to start [against Belgium]. I think he’ll have gained more confidence from the spell he had [as a substitute] and so, all being well, we hope he’ll be good to start on Wednesday.”

Source Article

CytRx Highlights Use of Licensed Drug Aldoxorubicin in Treatment of Former Senate Majority Leader Harry Reid’s Pancreatic Cancer

Reid’s Stage IV Pancreatic Cancer is Reportedly in “Complete Remission” After Combination Immunotherapy That Included NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803 and Aldoxorubicin

ImmunityBio and NantKwest Announced in May 2020 That They Planned to Commence a Randomized Phase 2 Study of This Experimental Treatment for Pancreatic Cancer

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted the use of its licensed drug – aldoxorubicin – in the combination immunotherapy used by ImmunityBio, Inc. and NantKwest, Inc. to treat former Senate Majority Leader Harry Reid’s stage IV pancreatic cancer. It was widely reported in June 2020 that former Senator Reid described himself as being in “complete remission” after receiving experimental treatment pioneered by the Chief Executive Officer of ImmunityBio and NantKwest.1

Earlier this year, CytRx highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88). The study received Food and Drug Administration (“FDA”) authorization and was slated to initially enroll 268 subjects across both cohorts. It has been indicated that enrollment was expected to begin in June 2020.

“We wish former Senator Reid the best now that he is reportedly in complete remission and hope that his combination immunotherapy treatment can become the basis for treating other individuals with pancreatic cancer,” said Steven A. Kriegsman, CytRx’s Chairman and CEO. “Although former Senator Reid is only one person and other comprehensive studies and trials are necessary and required, we continue to be encouraged with the progress and results of this promising pancreatic cancer treatment that includes aldoxorubicin.”

CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343 million in potential milestone payments as well as prospective royalties on sales of aldoxorubicin.

About CytRx Corporation

CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s other drug candidate, arimoclomol, was sold to Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporation’s website is www.cytrx.com.

About Pancreatic Cancer

Pancreatic cancer kills an estimated 47,000 people annually; it is the fourth leading cause of cancer-related death in the U.S., and 57,600 new cases are expected in 2020. Less than 5% of these patients will live for more than five years after diagnosis, and the median survival prognosis is 5 to 8 months. Pancreatic cancer is a disease in which malignant (cancerous) cells form in the tissues of